VBS Fellows’ Foray 2022 – Retina’s Believe It or Not: Case-Based Examples and Real-World Treatment Strategies

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

VBS Board Moderators:

Anton Orlin, MD
Associate Professor of Ophthalmology
Weill Cornell Medical College
New York, NY

D. Wilkin Parke III, MD
VitreoRetinal Surgery, PA Co-director
Vitreoretinal Surgery Fellowship Program
Minneapolis, MN

Aleksandra V. Rachitskaya, MD
Assistant Professor of Ophthalmology
Cole Eye Institute, Cleveland Clinic
Cleveland, OH

Camila Ventura, MD, PhD
Department of Ophthalmology Retina Specialist Department of Research,
Director, Altino Ventura Foundation (FAV)
Hope Eye Hospital Recife
Pernambuco, Brazil

Panelists:

Fellows:

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.

Moderators:
Anton Orlin, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: EyePoint Pharmaceuticals.

D. Wilkin Parke III, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Genentech, RegenxBio; Royalties: Vortex Surgical.

Aleksandra V. Rachitskaya, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Carl Zeiss Meditec, Genentech; Grant/Research Support: Apellis, AGTC, Genentech, Novartis; Speaker’s Bureau: Apellis, Genentech, Regeneron Pharmaceuticals.

Camila Ventura, MD, PhD, has had no financial relationships with ineligible companies.

Panelists:
Margaret Chang, MD, MS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Genentech, RegenxBio; Grant/Research Support: Allergan, Mylan, NGM Bio, Novartis, Opthea, Ophthotech, Regeneron Pharmaceuticals.

Yewlin E. Chee, MD, has had no financial relationships with ineligible companies.

David R. Chow MD, FRCS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch + Lomb, Bayer, Dutch Ophthalmic, Katalyst Surgical, Roche; Grant/Research Support: Bayer, Novartis, Roche; Speaker’s Bureau: Optovue.

Sunil K. Srivastava, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotechnologies, Bausch + Lomb, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Eyevensys, Novartis; Grant/Research Support: Bausch + Lomb, EyePoint Pharmaceuticals, Eyevensys, Regeneron Pharmaceuticals.

Fellows:
Riyaz Bhikoo, MBChB, FRANZCO, Daniel Brill, MD, Diana M. Laura, MD, Wei Wei Lee, MD, Danny A. Mammo, MD, Nita Valikodath, MD, MS, Marcelo C. Ventura Filho, MD, Sushant Wagley, MD, have had no financial relationships with ineligible companies.

The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.